The Role of Leukotriene Receptor Antagonists (LTRAs) in the Management of Asthma

Feldberg W. Kellaway C.H. . Liberation of histamine and formation of lysocithin like substances by cobra venom. J Physiol 1938; 94: 187–226.

Hay D.W.P. . Pharmacology of Leukotriene Receptor Antagonists. More than inhibitors of bronchoconstriction, Chest 1997; 111; 35–45

Spector S.L. . Leukottiene inhibitors and antagonists in asthma. Annals of Allergy, Asthma and Immunology 1995; 75/6 part 1: 463–70.

Reiss T.F. Chervinsky P. Dockhorn RJ . Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicentre, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 1998; 158 (11): 1213–1220.

Reiss T.F. Altman L.C. Munk ZM MK-0476, an LTD4 receptor antagonist, improves the signs and symptoms of asthma with a dose as low as 10mg once daily [abstract]. Am J Respir Crit Care Med 1995; 151: A378.

Reiss T.F. Chervinsky P. Noonan M. MK-0476, an LTD4 receptor antagonist, exhibits a dose related improvement in the once daily treatment of patients with chronic asthma [abstract] Eur Respir J 1995; 19: 289s.

Reiss T.F. Chervinsky P. Edwards T. Montelukast (MK-0476), a cysLTl receptor antagonist, improves the signs and symptoms of asthma over a 3 month treatment period [abstract]. Eur Respir J 1996; 9: 273s.

Fish JE. Kemp JP. Lockey R.F. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clinical Therapeutics 1997; 19 (4): 675–90.

Knorr B. Matz L. Bernstein JA. Montelukast for chronic asthma in 6- to 14-year-old children. A randomised, double-blind trial. JAMA 1998; 279: 1181–86.

Leff J.A. Busse W.W. Pearlman D Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339: 147–52.

Leff J.A. Pizzichini E. E. Fthimiadis A. Effects of montelukast (MK-0476) on airway eosinophilic inflammation in mildly uncontrolled asthma: a randomised placebo-controlled trial. Am J Respir Care Med, 1997, 155 (4): 977

Calhoun W.J. Lavins B.J. Minkwitz M.C. Effect of zafirlukast (Accolate) on cellular mediators of inflammation: bronchoalveolar lavage fluid findings after segmental antigen challenge. Am J Respir Crit Care Med 1998; 157 (5 Pt 1): 1381–89.

Leff J.A. Busse W.W. Pearlman D. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339 (3): 147–52.

Fish JE. Kemp JP. Lockey R.F. Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther 1997; 19 (4): 675–90.

Adkins JC. Brogden R.N. Zafirlukast . A review of its pharmacology and therapeutic potential in the management of asthma. Drugs 1998; 55 (1): 121–44.